Daniel S. Levine

A study shows that television commercials are rife with opinion and lifestyle associations but more often than not they also make misleading or false claims.

Paying doctors based on how well their patients did and paying them more to treat high-risk patients produces better outcomes than traditional fee-for-service compensation.

Annual premiums for employer-sponsored family health coverage increased 4% from a year ago. The relatively modest increase well outpaced the growth in workers' wages and general inflation during the same period.

Report finds doctors with financial interest in radiation treatment centers more likely to provide the therapy to prostate cancer patients than other doctors.

Around the world governments are seeking to address the financial threat they see obesity posing to the wellness of their health care systems and New Zealand represents a new front in the war on obesity.

While Americans see promise in biomedical advances, they are skeptical about treatments to extend life expectancy becoming a reality any time soon. Plus, most say they wouldn't want to live so long.

In an overhaul of the tax system, the orphan drug tax credit could get thrown out. According to advocates, this is the biggest issue facing the rare disease community.

Advocates of clinical trials data sharing blast a new proposal of principles from American and European pharmaceutical groups as "window dressing" that fall short of actual concrete commitments.

The FDA is seeking to end restrictions on labeling revisions by generic drugmakers in a move that consumer advocates say could improve safety for patients and create liability for companies.

Members of the American Medical Association voted to recognize obesity as a disease, which could have implications for the way insurance companies, employers, policymakers and others address a growing health care issue.

Nearly $1 billion will be made available in the second round of Health Care Innovation Awards for projects that have a "high likelihood" of cutting costs while delivering better outcomes.

Growth in health care spending has been slower than expected, in part because of the 2007 to 2009 recession, but a new study suggests the recession only explains part of the slowdown.

For drugmakers, the president's proposed budget represents a bit of déjà vu all over again. For the biopharmaceutical industry, the president's proposed budget calls for reducing exclusivity on biologics to seven years from 12 years.

A new report found one-in-three seniors in the United States dies with Alzheimer's disease or some other form of dementia, placing a growing burden on the nation's health care system.

Reports on CEO pay are delivering mixed news as the life sciences industry continues to move toward a greater linkage between pay and performance

As part of the government spending cuts triggered on March 1, $1.6 billion will be cut from the National Institutes of Health, which advocates say will slow research and reverberate throughout the economy.

There's growing concern in the life sciences industry that Congress will fail to reach an agreement that will avoid sequestration. Several influential Republicans think sequestration will hit.

The cost of drug development has been a matter of controversy, particularly because the high cost and long time to bring a drug from discovery to market is used to justify high prices for innovative drugs.

The United Kingdom's Medical Research Council is providing a total of $11 million in funding to 15 research projects that will seek to find new uses for 22 AstraZeneca compounds that had been studied but shelved for a variety of reasons.

The use of generic prescription drugs saved consumers and the U.S. health care system $1 trillion over the past decade with savings totaling $193 billion in 2011.

Osiris Therapeutics said it has received approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children.

Worried industry leads spending to minimize potential pain inflicted by deficit-cutting Supercommittee.

Twitter can potentially be used to monitor the public's health and its perceptions on various health-related issues.

Pharmaceutical Research and Manufacturers of America says proposals to cut government spending on drugs would threaten jobs.

Study finds the FDA is quicker at approving cancer drugs than its European counterpart.

Life expectancy in the U.S. is falling compared to the average 10 countries with the best life expectancy and researchers attribute the decrease to preventable risk factors.